ID   RPMI-8226/MR20
AC   CVCL_0509
SY   RPMI 8226/MR20; RPMI8226/MR20; 8226/MR20; 8226 MR20
DR   MCCL; MCC:0000407
DR   cancercelllines; CVCL_0509
DR   Wikidata; Q54951250
RX   PubMed=10070958;
RX   PubMed=10825126;
RX   PubMed=11309308;
RX   PubMed=12116365;
CC   Population: African American.
CC   Characteristics: Produces IgG lambda (from parent cell line).
CC   Selected for resistance to: ChEBI; CHEBI:50729; Mitoxantrone.
CC   Sequence variation: Gene fusion; HGNC; 5722; IGKJ4 + HGNC; 5783; IGKV2-28; Name(s)=IGKV2-28-IGKJ4 (from parent cell line).
CC   Sequence variation: Gene fusion; HGNC; 5865; IGLJ3 + HGNC; 5888; IGLV2-14; Name(s)=IGLV2-14-IGLJ3 (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Thr751Ile (c.2252C>T); ClinVar=VCV000177773; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Lys191Leufs*60; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: B-cell; CL=CL_0000236.
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_4V90 ! RPMI-8226/MR4
SX   Male
AG   61Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 19
//
RX   PubMed=10070958;
RA   Hazlehurst L.A., Foley N.E., Gleason-Guzman M.C., Hacker M.P.,
RA   Cress A.E., Greenberger L.M., de Jong M.C., Dalton W.S.;
RT   "Multiple mechanisms confer drug resistance to mitoxantrone in the
RT   human 8226 myeloma cell line.";
RL   Cancer Res. 59:1021-1028(1999).
//
RX   PubMed=10825126;
RA   Scheffer G.L., Maliepaard M., Pijnenborg A.C.L.M., van Gastelen M.A.,
RA   de Jong M.C., Schroeijers A.B., van der Kolk D.M., Allen J.D.,
RA   Ross D.D., van der Valk P., Dalton W.S., Schellens J.H.M.,
RA   Scheper R.J.;
RT   "Breast cancer resistance protein is localized at the plasma membrane
RT   in mitoxantrone- and topotecan-resistant cell lines.";
RL   Cancer Res. 60:2589-2593(2000).
//
RX   PubMed=11309308;
RA   Maliepaard M., Scheffer G.L., Faneyte I.F., van Gastelen M.A.,
RA   Pijnenborg A.C.L.M., Schinkel A.H., van de Vijver M.J., Scheper R.J.,
RA   Schellens J.H.M.;
RT   "Subcellular localization and distribution of the breast cancer
RT   resistance protein transporter in normal human tissues.";
RL   Cancer Res. 61:3458-3464(2001).
//
RX   PubMed=12116365; DOI=10.1002/cyto.10111;
RA   Minderman H., Suvannasankha A., O'Loughlin K.L., Scheffer G.L.,
RA   Scheper R.J., Robey R.W., Baer M.R.;
RT   "Flow cytometric analysis of breast cancer resistance protein
RT   expression and function.";
RL   Cytometry 48:59-65(2002).
//